- Home
- CMPX vs KYTX Comparison
CMPX vs KYTX Comparison
Compare CMPX & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- KYTX
- Stock Information
- Founded
- CMPX 2014
- KYTX 2018
- Country
- CMPX United States
- KYTX United States
- Employees
- CMPX N/A
- KYTX N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- KYTX
- Sector
- CMPX Health Care
- KYTX
- Exchange
- CMPX Nasdaq
- KYTX NYSE
- Market Cap
- CMPX 236.7M
- KYTX 242.1M
- IPO Year
- CMPX N/A
- KYTX 2024
- Fundamental
- Price
- CMPX $1.38
- KYTX $4.35
- Analyst Decision
- CMPX Strong Buy
- KYTX Buy
- Analyst Count
- CMPX 3
- KYTX 5
- Target Price
- CMPX $7.67
- KYTX $23.40
- AVG Volume (30 Days)
- CMPX 513.3K
- KYTX 237.0K
- Earning Date
- CMPX 11-12-2024
- KYTX 11-13-2024
- Dividend Yield
- CMPX N/A
- KYTX N/A
- EPS Growth
- CMPX N/A
- KYTX N/A
- EPS
- CMPX N/A
- KYTX N/A
- Revenue
- CMPX $850,000.00
- KYTX N/A
- Revenue This Year
- CMPX N/A
- KYTX N/A
- Revenue Next Year
- CMPX $747.71
- KYTX N/A
- P/E Ratio
- CMPX N/A
- KYTX N/A
- Revenue Growth
- CMPX N/A
- KYTX N/A
- 52 Week Low
- CMPX $0.77
- KYTX $4.32
- 52 Week High
- CMPX $2.34
- KYTX $30.60
- Technical
- Relative Strength Index (RSI)
- CMPX 31.85
- KYTX 33.83
- Support Level
- CMPX $1.74
- KYTX $5.01
- Resistance Level
- CMPX $2.00
- KYTX $5.62
- Average True Range (ATR)
- CMPX 0.14
- KYTX 0.39
- MACD
- CMPX -0.04
- KYTX -0.03
- Stochastic Oscillator
- CMPX 6.06
- KYTX 2.19
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.